English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Proteus mirabilis resistant to expanded-spectrum cephalsoporins (ESC) is an emerging problem. In addition to extended-sectrum -lactamases (ESBLs), acquired AmpC-type -lactamases represent an important mechanism of resistance  to ESC in P. mirabilis, at least in some countries. Distinction of clinical isolates producing an ESBL or an AmpC-type enzyme is a matter of interest for the implications in surveillance, infection control, and treatment issues. This work describes a simple and practical Double Synergy Differential Test (DSDT) that couples the detection of ESBLs and AmpC-type enzymes by means of a combo-disk approach using cefotaxime and ceftazidime as indicator substrates, and clavulanate and boronic acid as enzyme inhibitors. The DSDT was tested with a collection of 104 P. mirabilis with different beta-lactamase profiles, and  proved to be highly sensitive and specific for the detection of ESBL- and AmpC-producing isolates

Double Synergy Differential Test for detection of plasmid-mediated AmpC-type β-lactamases in Proteus mirabilis